New Website News: Generex Biotechnology Announces
Post# of 36537
(Total Views: 131)
Posted On: 01/08/2019 8:24:19 AM
New Website News:
Generex Biotechnology Announces the Launch of a New Corporate Website
8:00 AM ET, 01/08/2019 - Business Wire
www.generex.com Life Science Holdings Corporate Strategy New organizational structure with the NuGenerex Family of subsidiary companies Management Team
MIRAMAR, Fla.--(BUSINESS WIRE)--Jan. 8, 2019-- Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has relaunched its corporate website to provide details on a revamped organizational structure, a talented and experienced management team, and a forward-looking vision for Generex as an integrated life science holdings company. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care. You can visit the site at www.generex.com.
Generex has reorganized its portfolio of immuno-oncology assets, medical devices, and diagnostics as a family of NuGenerex subsidiary companies, and expanded the business focus through acquisitions of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization (MSO) with a network of over 400 physicians and expansion opportunities from 5 to 27 states, a network of pharmacies across the U.S., a clinical laboratory with specialty diagnostic services, and two regenerative medicine companies, Regentys and Olaregen that have been announced this week.
Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.
“We have worked diligently over the last two years on this considerable reorganization, and we are proud to share the results of our efforts and our vision for the future of Generex Biotechnology as a healthcare holding company that adds significant value for our shareholders and investors,” said Joe Moscato, CEO of Generex. “We have organized our businesses as independently operating subsidiaries under the umbrella of the NuGenerex Family of Companies, highlighting the intra-company synergies that allow for cross-company business and integrated sales. Further, we are acquiring companies like Regentys and Olaregen that fit with our strategic model to provide end-to-end solutions for patients and doctors. As you will see when you visit the site, we have transformed Generex into a new kind of healthcare company, with proprietary products and service lines that drive revenue to support the clinical development of innovative therapies and value for our investors.”
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.
Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190108005349/en/
Source: Generex Biotechnology Corporation
Generex Biotechnology CorporationJoseph Moscato646-599-6222Todd Falls800-391-6755 Extension 222investor@generex.com
Price Performance Comparison
Price Performance Comparison Table
Index Comparison 1 Month 6 Months 1 Year 52-Week Range
GNBT:OTCQB
+95.00% +1,155.13% +718.98% Percentile : 50.6205014076586%
S&P US Health Care -4.32% -2.03% +1.25% Percentile : 37.3574031441352%
S&P Global Health Care -3.47% -3.69% -2.15% Percentile : 33.9720890388179%
S&P 500 -3.34% -8.42% -7.05% Percentile : 34.1746167953831%
S&P Global BMI -2.10% -9.70% -12.33% Percentile : 24.6150747494187%
ETFs Holding This Company
ETFs Holding this Company Table
Symbol Name Morningstar Category % of Fund 52-Week Range
No ETFs Available
Company Profile
Business Summary
Generex Biotechnology Corporation is a development-stage company. The Company is engaged in the research and development of drug delivery systems and technologies. The Company is involved in the development of a platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones and vaccines. The Company's subsidiary, Antigen Express, Inc. (Antigen), is engaged in research and development of technologies and immunomedicines for the treatment of malignant, infectious, autoimmune and allergic diseases. The Company holds interests in Hema Diagnostic Systems, LLC (Hema). Hema is in the business of developing, manufacturing, and distributing of in-vitro medical diagnostics for infectious diseases administered at the point of care level. Hema manufactures and sells rapid diagnostic devices based upon its own EXPRESS technology, as well as cassette devices based on customary designs used in the industry.
ExecutivesContact Information
Joseph Moscato
Chairman of the Board, President, Chief Executive Officer
Mark Corrao
Chief Financial Officer, Treasurer
Terry Thompson
Chief Operating Officer
Jacob Dagan
Executive Vice President, Business Development.
Andrew Ro
Senior Vice President of Investments, Chief Investment Officer, Director
Richard Purcell
Senior Vice President of Research & Drug Development.
Website
http://www.generex.com/
Investor Contact
Todd Falls
Office
10102 USA Today Way
MIRAMAR, FL 33025-3903
Phone
(416) 364-2551
Fax
(302) 655-5049
Generex Biotechnology Announces the Launch of a New Corporate Website
8:00 AM ET, 01/08/2019 - Business Wire
www.generex.com Life Science Holdings Corporate Strategy New organizational structure with the NuGenerex Family of subsidiary companies Management Team
MIRAMAR, Fla.--(BUSINESS WIRE)--Jan. 8, 2019-- Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has relaunched its corporate website to provide details on a revamped organizational structure, a talented and experienced management team, and a forward-looking vision for Generex as an integrated life science holdings company. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care. You can visit the site at www.generex.com.
Generex has reorganized its portfolio of immuno-oncology assets, medical devices, and diagnostics as a family of NuGenerex subsidiary companies, and expanded the business focus through acquisitions of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization (MSO) with a network of over 400 physicians and expansion opportunities from 5 to 27 states, a network of pharmacies across the U.S., a clinical laboratory with specialty diagnostic services, and two regenerative medicine companies, Regentys and Olaregen that have been announced this week.
Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.
“We have worked diligently over the last two years on this considerable reorganization, and we are proud to share the results of our efforts and our vision for the future of Generex Biotechnology as a healthcare holding company that adds significant value for our shareholders and investors,” said Joe Moscato, CEO of Generex. “We have organized our businesses as independently operating subsidiaries under the umbrella of the NuGenerex Family of Companies, highlighting the intra-company synergies that allow for cross-company business and integrated sales. Further, we are acquiring companies like Regentys and Olaregen that fit with our strategic model to provide end-to-end solutions for patients and doctors. As you will see when you visit the site, we have transformed Generex into a new kind of healthcare company, with proprietary products and service lines that drive revenue to support the clinical development of innovative therapies and value for our investors.”
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.
Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190108005349/en/
Source: Generex Biotechnology Corporation
Generex Biotechnology CorporationJoseph Moscato646-599-6222Todd Falls800-391-6755 Extension 222investor@generex.com
Price Performance Comparison
Price Performance Comparison Table
Index Comparison 1 Month 6 Months 1 Year 52-Week Range
GNBT:OTCQB
+95.00% +1,155.13% +718.98% Percentile : 50.6205014076586%
S&P US Health Care -4.32% -2.03% +1.25% Percentile : 37.3574031441352%
S&P Global Health Care -3.47% -3.69% -2.15% Percentile : 33.9720890388179%
S&P 500 -3.34% -8.42% -7.05% Percentile : 34.1746167953831%
S&P Global BMI -2.10% -9.70% -12.33% Percentile : 24.6150747494187%
ETFs Holding This Company
ETFs Holding this Company Table
Symbol Name Morningstar Category % of Fund 52-Week Range
No ETFs Available
Company Profile
Business Summary
Generex Biotechnology Corporation is a development-stage company. The Company is engaged in the research and development of drug delivery systems and technologies. The Company is involved in the development of a platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones and vaccines. The Company's subsidiary, Antigen Express, Inc. (Antigen), is engaged in research and development of technologies and immunomedicines for the treatment of malignant, infectious, autoimmune and allergic diseases. The Company holds interests in Hema Diagnostic Systems, LLC (Hema). Hema is in the business of developing, manufacturing, and distributing of in-vitro medical diagnostics for infectious diseases administered at the point of care level. Hema manufactures and sells rapid diagnostic devices based upon its own EXPRESS technology, as well as cassette devices based on customary designs used in the industry.
ExecutivesContact Information
Joseph Moscato
Chairman of the Board, President, Chief Executive Officer
Mark Corrao
Chief Financial Officer, Treasurer
Terry Thompson
Chief Operating Officer
Jacob Dagan
Executive Vice President, Business Development.
Andrew Ro
Senior Vice President of Investments, Chief Investment Officer, Director
Richard Purcell
Senior Vice President of Research & Drug Development.
Website
http://www.generex.com/
Investor Contact
Todd Falls
Office
10102 USA Today Way
MIRAMAR, FL 33025-3903
Phone
(416) 364-2551
Fax
(302) 655-5049
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼